S&P 500   2,988.75 (-0.23%)
DOW   27,003.02 (-0.08%)
QQQ   192.80 (-0.37%)
AAPL   233.94 (-0.59%)
FB   189.04 (+0.08%)
MSFT   140.18 (-0.98%)
GOOGL   1,242.70 (+0.04%)
AMZN   1,778.81 (+0.65%)
CGC   19.68 (-2.09%)
NVDA   194.06 (-1.18%)
BABA   176.78 (+0.85%)
TSLA   258.56 (+0.26%)
T   37.82 (-0.24%)
F   9.08 (+0.11%)
ACB   3.65 (-2.93%)
PRI   123.48 (-0.15%)
NFLX   286.66 (+0.85%)
BAC   30.37 (+2.15%)
GILD   65.42 (+0.18%)
S&P 500   2,988.75 (-0.23%)
DOW   27,003.02 (-0.08%)
QQQ   192.80 (-0.37%)
AAPL   233.94 (-0.59%)
FB   189.04 (+0.08%)
MSFT   140.18 (-0.98%)
GOOGL   1,242.70 (+0.04%)
AMZN   1,778.81 (+0.65%)
CGC   19.68 (-2.09%)
NVDA   194.06 (-1.18%)
BABA   176.78 (+0.85%)
TSLA   258.56 (+0.26%)
T   37.82 (-0.24%)
F   9.08 (+0.11%)
ACB   3.65 (-2.93%)
PRI   123.48 (-0.15%)
NFLX   286.66 (+0.85%)
BAC   30.37 (+2.15%)
GILD   65.42 (+0.18%)
Log in

Advaxis Stock Price, News & Analysis (NASDAQ:ADXS)

$0.32
-0.01 (-3.08 %)
(As of 10/16/2019 03:33 PM ET)
Today's Range
$0.30
Now: $0.32
$0.32
50-Day Range
$0.25
MA: $0.32
$0.41
52-Week Range
$0.21
Now: $0.32
$11.63
Volume4.31 million shs
Average Volume13.12 million shs
Market Capitalization$5.42 million
P/E RatioN/A
Dividend YieldN/A
Beta3.16
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADXS
CUSIPN/A
Phone609-452-9813

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.06 million
Book Value$5.18 per share

Profitability

Net Income$-66,510,000.00
Net Margins-113.67%

Miscellaneous

Employees58
Market Cap$5.42 million
Next Earnings Date1/9/2020 (Estimated)
OptionableOptionable

Receive ADXS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.


Advaxis (NASDAQ:ADXS) Frequently Asked Questions

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

How were Advaxis' earnings last quarter?

Advaxis, Inc. (NASDAQ:ADXS) released its quarterly earnings results on Tuesday, March, 12th. The biotechnology company reported $0.18 earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.43. The biotechnology company earned $19.69 million during the quarter. Advaxis had a negative net margin of 113.67% and a negative return on equity of 67.08%. View Advaxis' Earnings History.

When is Advaxis' next earnings date?

Advaxis is scheduled to release their next quarterly earnings announcement on Thursday, January 9th 2020. View Earnings Estimates for Advaxis.

What price target have analysts set for ADXS?

1 analysts have issued 12-month price targets for Advaxis' shares. Their predictions range from $4.00 to $4.00. On average, they expect Advaxis' stock price to reach $4.00 in the next year. This suggests a possible upside of 1,169.8% from the stock's current price. View Analyst Price Targets for Advaxis.

What is the consensus analysts' recommendation for Advaxis?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Advaxis.

What are Wall Street analysts saying about Advaxis stock?

Here are some recent quotes from research analysts about Advaxis stock:
  • 1. According to Zacks Investment Research, "Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P. " (10/14/2019)
  • 2. HC Wainwright analysts commented, "We maintain our Neutral rating of ADXS and our 12-month price target of $4.30 per share. We derive our price target based on the average of two valuation methods: (1) price-sales multiple (6x 2026 sales estimate at 20% discount); and (2) price-earnings multiple (19x 2026 earnings estimate at 20% discount)." (6/12/2019)

Has Advaxis been receiving favorable news coverage?

Media coverage about ADXS stock has trended positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Advaxis earned a news impact score of 2.1 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Advaxis.

Are investors shorting Advaxis?

Advaxis saw a decrease in short interest during the month of September. As of September 15th, there was short interest totalling 235,600 shares, a decrease of 61.7% from the August 15th total of 615,600 shares. Based on an average trading volume of 1,880,000 shares, the short-interest ratio is presently 0.1 days. Approximately 1.0% of the shares of the stock are short sold. View Advaxis' Current Options Chain.

Who are some of Advaxis' key competitors?

What other stocks do shareholders of Advaxis own?

Who are Advaxis' key executives?

Advaxis' management team includes the folowing people:
  • Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 55)
  • Ms. Molly Henderson CPA, CPA, MBA, Exec. VP, CFO & Corp. Sec. (Age 48)
  • Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 59)
  • Mr. Anthony A. Lombardo, Exec. Officer (Age 70)
  • Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 58)

How do I buy shares of Advaxis?

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Advaxis' stock price today?

One share of ADXS stock can currently be purchased for approximately $0.32.

How big of a company is Advaxis?

Advaxis has a market capitalization of $5.42 million and generates $6.06 million in revenue each year. The biotechnology company earns $-66,510,000.00 in net income (profit) each year or ($19.34) on an earnings per share basis. Advaxis employs 58 workers across the globe.View Additional Information About Advaxis.

What is Advaxis' official website?

The official website for Advaxis is http://www.advaxis.com/.

How can I contact Advaxis?

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]


MarketBeat Community Rating for Advaxis (NASDAQ ADXS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  337 (Vote Outperform)
Underperform Votes:  353 (Vote Underperform)
Total Votes:  690
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Featured Article: What is the Bid-Ask Spread?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel